$1.93
(Market cap
$9,339 Mln
Recently Viewed
Clear AllMarket cap
$9,339 Mln
Revenue (TTM)
$1,091 Mln
P/E Ratio
41.7
P/B Ratio
15.7
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
0.8 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
22.5
Debt to Equity
0.3
Book Value
$--
EPS
$1.5
Face value
--
Shares outstanding
140,032,190
CFO
$-277.87 Mln
EBITDA
$-815.57 Mln
Net Profit
$-860.32 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Arrowhead Pharmaceuticals (ARWR)
| 4.7 | 21.2 | 8.9 | 512.4 | 31.7 | 0.5 | 27.3 |
|
BSE Sensex
| -7.3 | 4.0 | -6.1 | 1.9 | 9.1 | 10.0 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Arrowhead Pharmaceuticals (ARWR)
| 253.1 | -38.3 | -24.6 | -38.8 | -13.6 | 21.0 | 410.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Arrowhead Pharmaceuticals (ARWR)
|
69.5 | 9,338.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 41.7 | 15.7 |
| 244.5 | 15,338.5 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 78.1 | |
| 66.7 | 8,171.9 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.9 | 12,295.6 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.5 | 5.4 | |
| 90.4 | 11,333.1 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 68.7 | 7,974.5 | 1,396.6 | 316.9 | 59.8 | 153.6 | 26.2 | 162.6 | |
| 530.2 | 12,043.3 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.0 | |
| 521.5 | 14,850.2 | 2,530.2 | 451.1 | 21.3 | 70.2 | 34 | 32.3 | |
| 107.0 | 8,256.4 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 339.8 | 9,569.6 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of... angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California. Address: 177 East Colorado Boulevard, Pasadena, CA, United States, 91105 Read more
CEO, President & Director
Dr. Christopher R. Anzalone Ph.D.
CEO, President & Director
Dr. Christopher R. Anzalone Ph.D.
Headquarters
Pasadena, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Arrowhead Pharmaceuticals Inc (ARWR) is $69.91 (NASDAQ) as of 17-Apr-2026 16:06 EDT. Arrowhead Pharmaceuticals Inc (ARWR) has given a return of 31.66% in the last 3 years.
The P/E ratio of Arrowhead Pharmaceuticals Inc (ARWR) is 41.68 times as on 15-Apr-2026.
The P/B ratio of Arrowhead Pharmaceuticals Inc (ARWR) is 15.71 times as on 15-Apr-2026, a 242 premium to its peers’ median range of 4.59 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2,869.63
|
10.04
|
|
2024
|
-3.94
|
12.74
|
|
2023
|
-14.05
|
10.63
|
|
2022
|
-19.80
|
8.77
|
|
2021
|
-46.33
|
15.96
|
The 52-week high and low of Arrowhead Pharmaceuticals Inc (ARWR) are Rs 76.76 and Rs 10.92 as of 19-Apr-2026.
Arrowhead Pharmaceuticals Inc (ARWR) has a market capitalisation of $ 9,339 Mln as on 15-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Arrowhead Pharmaceuticals Inc (ARWR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.